(redirected from disease-specific mortality)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
References in periodicals archive ?
The authors' show that there is evidence of a reduction in mortality in only 30% of the disease-specific mortality estimates and 11% of the all-cause mortality estimates from the randomised controlled trials they evaluated.
Moreover, future detailed population-based and translational studies may increase insight into causal factors of higher disease-specific mortality and breast cancer relapse with increasing age," they added.
We consistently found that surgery did not reduce [either all-cause or disease-specific] mortality for men with PSA levels less than or equal to 10, and we consistently found that radical prostatectomy reduced both overall and disease-specific mortality in men with PSAs above 10," he said in the interview.
Disease-specific mortality is not improved and the cost per life-year gained is not a rational expense with routine supplemental ultrasonography
The authors of this study compared disease-specific mortality changes to all-cause mortality changes in a collection of cancer screening trials.
Disease-specific mortality was 35% for men diagnosed in the screening group and 45% for controls; overall mortality for men with prostate cancer was 81% in the screening group and 86% in controls.
Consumption of whole grains, especially the bran component of whole grains, was associated with a significant decrease in the risk of all-cause mortality and cardiovascular disease-specific mortality in women with type 2 diabetes who were followed as part of the Nurses' Health Study.
Major Finding: Women with type 2 diabetes in the highest quintile of bran consumption had a 28% lower risk of all-cause mortality and 35% lower risk of cardiovascular disease-specific mortality than women in the lowest quintile.
The new guidelines recommend that PET scans also may be used as part of initial staging in poorly differentiated thyroid cancers and invasive Hurthle cell carcinomas, as a prognostic tool in patients with metastatic disease to identify those patients at highest risk of rapid disease progression and disease-specific mortality, and as an evaluation of posttreatment response following systemic or local therapy of metastatic or locally invasive disease.